Global Sialorrhea Market – Industry Trends and Forecast to 2029

Sialorrhea Market Analysis and Size

The global sialorrhea market is expected to witness significant growth during the forecast period. Different therapies in development for myelofibrosis focus in a broader variety of targets. The majority of the pipeline drugs are administered through the oral route. Novartis has the maximum number of completed clinical trials for myelofibrosis, with 15 trials. It has been said that no drug therapy can cure myelofibrosis. Allogeneic stem cell transplantation is the only cure for myelofibrosis, but this process is risky for older patients and those with other health problems. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global sialorrhea market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Sialorrhea Market Scope and Segmentation

Market Definition

Sialorrhea, also called ptyalism, is a condition in which excessive production or presence of saliva in the oral cavity can result in drooling. It is caused by either hypersecretion of saliva or anatomical or motor dysfunction. Sialorrhea is a common problem in the neurologically impaired and in adults who have Parkinson's disease or have had a stroke. It is most commonly caused by poor oral and facial muscle control.

Global Sialorrhea Market Dynamics

Drivers

• Higher demands of Oral gels and liquids

Oral gels and oral liquids are recommended choices in the market for their ease of use. Oral gels and oral liquids help in stimulating compliance as these products are typically associated with oral hygiene in contrast to tablets that have reduced compliance rates. Among the two, oral liquids have higher potential as the segment is projected to be worth almost US$ 420 million by the end of the eight-year study., which in return is increasing the demand for this drug and supporting the growth of the segment.

• Increasing Incidence in Elderly Population

Myelofibrosis cases are primarily witnessed in the age group ≤ 40 years, 41−60 years, and > 60 years. The >60 years group saw the highest number of patients mostly around 10,275 in 2021 in the U.S. In 2021, the treatment-eligible population of myelofibrosis accounted for 9,511 cases in the U.S. This boosts the market growth.

Opportunities

• Rising R&D and New Drug Approvals

The unmet needs of patients suffering from myelofibrosis are encouraging manufacturers to innovate new solutions. The rising investments in the research and development activities to develop a precise treatment for sialorrhea is anticipated to boost the growth of the industry in the forecast period. The speedy technological advancements and ongoing clinical trials are contributing to the industry growth. Other factors such as improved healthcare sector, reimbursement policies, favourable government initiatives, busy lifestyles and changing dietary patterns are also resulting in the industry growth.   

• Varied New Treatments

Several treatment methods are boosting the growth of the market. The first liquid medication for the treatment of sialorrhea approved by the FDA was Cuvposa, which was launched in the U.S. market in April 2011. In some cases, surgery can be done to reduce the saliva secretion by re-routing the salivary glands or repositioning them in such a way that saliva is released at the back end of the mouth. This makes it smoother for the patient to swallow. These new treatment methods are creating more opportunities for the market.

 Restraints/Challenges

• Higher Availability of Alternatives

The number of alternatives available for the treatment of sialorrhea including acupuncture, herbal medicines, and salivary stimulants, are hindering the market growth.

• High Cost

The huge expenditure associated with these agents hamper the market growth. The huge drug development and the associated processes hamper the market's growth.

This global sialorrhea market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global sialorrhea market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Global Sialorrhea Market Scope

The global sialorrhea market is segmented on the basis of type, drugs, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Posterior Sialorrhea
• Anterior Sialorrhea

Drugs

• IncobotulinumtoxinA
• RimabotulinumtoxinB
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Sialorrhea Market Regional Analysis/Insights

The global sialorrhea market is analysed and market size insights and trends are provided by type, drugs, distribution channel and end-user as referenced above.

The major countries covered in the global sialorrhea market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing positive growth for the global sialorrhea market throughout the forecasted period due to advanced healthcare facilities and the presence of multiple treatment options.

North America dominates the market due to increased public–private partnerships to promote R&D activities for treatment of sialorrhea in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Sialorrhea Market Share Analysis

The global sialorrhea market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global sialorrhea market.

Key players operating in the global sialorrhea market include:

• Pfizer Inc (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Mylan N.V. (U.S.)
• Fresenius Kabi AG (Germany)
• Hikma Pharmaceuticals PLC (U.K.)
• Novartis AG (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Bristol Myers Squibb Company (U.S.)
• GSK Plc. (U.K.)
• Bayer AG (Germany)
• Sun Pharmaceutical Industries Ltd (India)
• Merz Pharma (Germany)
• USWM, LLC. (U.S.)

SKU-54367